Editas Medicine, Inc. (EDIT): Net Income
-$160.06M
Year ended 2025-12-31
-$73.95M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$160.06M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$237.09M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$153.22M | n/m | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | -$220.43M | n/m | 2025-03-05, From 2022-01-01 |
| 2021-12-31 | -$192.50M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$115.98M | n/m | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | -$133.75M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$109.95M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$120.32M | n/m | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | -$97.18M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$72.90M | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | -$13.69M | n/a | 2017-03-03, From 2014-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$160.06M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$119.72M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$122.93M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$311.35M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | -$9.74M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$104.99M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$79.20M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$45.72M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$6.60M | n/m |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗